Huntington's Disease Market Report

1. Huntington's Disease Market Growth Anticipated by 2032 | Major Pharma Players: Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech The latest report titled "Huntington's Disease Market Insights, Epidemiology and Market Forecast 2032" by DelveInsight projects a significant upswing in the Huntington's Disease market between 2019 and 2032. This growth is expected to be driven by various factors, including the introduction of innovative treatments, a rise in disease prevalence, an aging population, increased focus on research and development, and the advent of genetic testing. The report provides insights into current treatment practices for Huntington's Disease, upcoming drugs in the pipeline, market shares of different therapies, and the projected trajectory of the market size for Huntington's Disease across the 7MM (the United States, the EU-4 comprising Italy, Spain, France, and Germany, the United Kingdom, and Japan) during the specified period. Driving Forces Behind the Huntington's Disease Market Growth The growth of the Huntington’s disease market is expected to be mainly driven by entry of innovative emerging therapies, rising prevalence, and geriatric population, increasing initiatives for R&D, and the advent of genetic testing. Discover the Anticipated Evolution and Growth of the Market @ Huntington's Disease Therapeutics Market Forecast Huntington's Disease Overview: Huntington's disease is a hereditary neurological disorder that progressively affects brain function, leading to various physical, cognitive, and psychiatric symptoms. It is caused by

2. a mutation in the HTT gene, leading to the production of a faulty protein called huntingtin, which damages nerve cells in the brain. Huntington's disease symptoms: Huntington's disease symptoms typically start between the ages of 30 and 50, although they can appear at any age. Early signs might include involuntary movements (chorea), difficulty with coordination and balance, cognitive decline, mood changes, and psychiatric symptoms such as depression or irritability. As the disease advances, individuals may experience worsening movement, cognitive decline, and behavioral changes. Huntington's disease genetic inheritance: Huntington's disease is an autosomal dominant genetic disorder, meaning that a child has a 50% chance of inheriting the mutated gene from a parent with the condition. If inherited, the child will eventually develop Huntington's disease, although the onset and severity can vary. Huntington's disease progression: Huntington's disease is a progressive condition, and symptoms typically worsen over time. Early stages may involve subtle changes in movement and behavior, while later stages can result in significant physical disability and cognitive impairment. Huntington's disease diagnosis: Diagnosis of Huntington's disease involves a combination of medical history, neurological examination, genetic testing to confirm the presence of the mutated HTT gene, and assessment of symptoms. Genetic counseling is often recommended for individuals considering testing due to the implications of a positive result. Huntington's disease treatment: There is currently no cure for Huntington's disease, and treatments focus on managing symptoms to improve the individual's quality of life. Medications may help control movement disorders, manage psychiatric symptoms, or address other specific symptoms. Therapies like physical and occupational therapy, speech therapy, and counseling can also be beneficial in managing symptoms and providing support. Key Facts Huntington's Disease Market Report: ● Key players such as Prilenia Therapeutics, Ionis Pharmaceuticals, Annexon, Vaccinex, Neurocrine Biosciences, SAGE Therapeutics, PTC Therapeutics, WaVe life Sciences, Novartis, Neurimmune Therapeutics, SOLA Biosciences, UniQure

3. Biopharma, Roche, Annexon, Inc., Azevan Pharmaceuticals, SOM Innovation Biotech SA, Asklepios BioPharmaceutical, Luye Pharma Group Ltd., BrainStorm Cell Therapeutics, Voyager Therapeutics, Passage Bio, Locana Bio, Ceptur Therapeutics, Enzerna Biosciences, AFFiRiS AG, Arvinas, Atalanta Therapeutics, Anima Biotech, and others are investigating its candidates for Huntington's Disease. ● Huntington's Disease pipeline includes the therapies such as Pridopidine, Tominersen, ANX-005, Pepinemab, Valbenazine, SAGE-718, PTC-518, WVE-003, AMT 130, Branaplam, NI-302, SOL-176, RO7234292, ANX005, SRX246, Bevantolol, SOM3355, BV-101 Gene Therapy, LPM3770164, Passage Bio Research Project, Huntington disease Research Project, BrainStorm Research Project, Locana Huntington disease Research Project, Ceptur Huntington Research Project, HTT RNA Research project, mHTT Research Project, AFFiRiS Huntington Research Project, HTT Research Project, Anima Biotech mHTT Research Project, and others. ● Som Biotech’s Phase II candidate SOM3355 (bevantolol) is a VMAT2 inhibitor being investigated for chorea associated with Huntington's disease. According to the company, SOM3355 differs from tetrabenazine in interaction with VMAT2 and inhibition of VMAT1, resulting in a balanced shift in monoamine signaling that alleviates motor symptoms of Huntington's disease while maintaining mental well-being. In October 2021, SOM Biotech announced that the US FDA had granted Orphan Drug Designation (ODD) for SOM3355 for the treatment of chorea movements in Huntington’s disease. ● In 2022, Stage II accounted for the highest number of diagnosed prevalent cases of Huntington’s disease. Whereas, Stage V accounted for the lowest number of cases. Huntington's Disease Epidemiology Segmentation: “In 2022, the age group of ≥60 accounted for approximately 50% of the total diagnosed prevalent cases of Huntington’s disease in the 7 MM.” ● As per DelveInsight’s analysis, in 2022, the total prevalent cases of Huntington’s disease were approximately 80,800 cases in the 7MM, which are expected to increase during the forecast period, i.e., 2023-2032.

4. ● As per DelveInsight’s analysis, in 2022, the total prevalent cases of Huntington’s disease, were approximately 80,800 cases in the 7MM, which are expected to increase during the forecast period, i.e., 2023-2032. ● In 2022, the prevalent cases of chorea associatedHuntington’s disease were around 72,700in the 7MM. The Huntington's Disease market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: • Total Prevalence of Huntington's Disease • Prevalent Cases of Huntington's Disease by severity • Gender-specific Prevalence of Huntington's Disease • Type-specific Prevalence of Huntington's Disease • Age-specific Prevalence of Huntington's Disease • Diagnosed Cases of Huntington's Disease DelveInsight's comprehensive report provides a thorough exploration of the Huntington's Disease market, covering key Huntington's Disease players, emerging Huntington's Disease therapies, treatment dynamics, and market challenges. For in-depth insights, access the full report @ Huntington's Disease Market Outlook 2032 Related Reports: Huntington's Disease Epidemiology Forecast Huntington's Disease Pipeline Insight Healthcare Consulting and Market Research Services by DelveInsight Discover how DelveInsight’s comprehensive analysis and proactive strategies facilitated a US-based pharmaceutical client’s triumphant entry into the European biosimilar landscape. Download Pharma Go-to-Market Case Study. Trending Reports by DelveInsight:

5. Adalimumab Biosimilar Market | Arbovirus Infection Market | Artificial Pancreas Device System Market | Dental Equipment Market | Gluten Sensitivity Market | Hypothyroidism Market | Inflammatory Bowel Disease Market | Mayus Kinase Jak Inhibitors Market | Mild Dry Eye Market | Mucopolysaccharidosis Market | Oncolytic Virus Cancer Therapy Market | Pyoderma Gangrenosum Market | Transdermal Drug Delivery Devices Market | Intrathecal Pumps Market | Hedgehog Pathway Inhibitors Market | Yellow Fever Market | Laryngeal Cancer Market | Female Infertility Market | Gender Dysphoria Market | Chronic Brain Damage Market | Spain Healthcare Outlook Market | Malignant Fibrous Histiocytoma Market | Asthma Diagnostic Devices Market | Chronic Obstructive Pulmonary Disease Treatment Devices Market | Airway Management Devices Market | Cough Assist Devices Market | Pulse Oximeters Market | Hemodialysis Catheter Devices Market | Chronic Spontaneous Urticaria Market | Gender Dysphoria Market | Germany Healthcare Outlook | Biopsy Devices Pipeline Insight | Bacterial Conjunctivitis Market | Infliximab Biosimilar Insight | Eosinophilic Asthma Market | Cushing Syndrome Market | Functional Dyspepsia Market | Peripherally Inserted Central Catheters (PICC) Devices Market About DelveInsight: DelveInsight is a prominent business consultant and market research firm specializing in the life sciences sector. With a focus on supporting pharmaceutical companies, DelveInsight provides end-to-end solutions to enhance their performance. Connect with DelveInsight: LinkedIn | Facebook | Twitter Contact Us: Kritika Rehani Team Lead, Marketing krehani@delveinsight.com +91-9650213330 www.delveinsight.com